Meiji Yasuda Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.33M | Buy |
12,740
+3,800
| +43% | +$1.68M | 0.28% | 107 |
|
|
2026
Q1 | $3.99M | Sell |
8,940
-281
| -3% | -$131K | 0.2% | 138 |
|
|
2025
Q4 | $4.18M | Sell |
9,221
-279
| -3% | -$120K | 0.2% | 148 |
|
|
2025
Q3 | $3.72M | Sell |
9,500
-133
| -1% | -$55.6K | 0.18% | 158 |
|
|
2025
Q2 | $4.29M | Sell |
9,633
-3,013
| -24% | -$1.39M | 0.21% | 142 |
|
|
2025
Q1 | $6.13M | Sell |
12,646
-617
| -5% | -$288K | 0.25% | 113 |
|
|
2024
Q4 | $5.34M | Buy |
13,263
+193
| +1% | +$89.5K | 0.2% | 132 |
|
|
2024
Q3 | $6.08M | Buy |
13,070
+160
| +1% | +$76.9K | 0.23% | 113 |
|
|
2024
Q2 | $6.05M | Buy |
12,910
+7,032
| +120% | +$3.05M | 0.25% | 112 |
|
|
2024
Q1 | $2.46M | Sell |
5,878
-3,381
| -37% | -$1.43M | 0.1% | 198 |
|
|
2023
Q4 | $3.77M | Buy |
9,259
+944
| +11% | +$349K | 0.17% | 162 |
|
|
2023
Q3 | $2.89M | Buy |
8,315
+3,046
| +58% | +$1.07M | 0.14% | 199 |
|
|
2023
Q2 | $1.85M | Sell |
5,269
-65
| -1% | -$21.9K | 0.09% | 219 |
|
|
2023
Q1 | $1.68M | Sell |
5,334
-3,716
| -41% | -$1.11M | 0.09% | 231 |
|
|
2022
Q4 | $2.61K | Sell |
9,050
-10,840
| -54% | -$3.3M | 0.13% | 201 |
|
|
2022
Q3 | $5.76M | Sell |
19,890
-381
| -2% | -$110K | 0.34% | 88 |
|
|
2022
Q2 | $5.71M | Sell |
20,271
-1,851
| -8% | -$495K | 0.33% | 80 |
|
|
2022
Q1 | $5.77M | Sell |
22,122
-1,084
| -5% | -$257K | 0.32% | 83 |
|
|
2021
Q4 | $5.1M | Buy |
23,206
+271
| +1% | +$52.7K | 0.32% | 86 |
|
|
2021
Q3 | $4.16M | Buy |
22,935
+410
| +2% | +$80K | 0.3% | 89 |
|
|
2021
Q2 | $4.54M | Sell |
22,525
-202
| -0.9% | -$42.3K | 0.22% | 99 |
|
|
2021
Q1 | $4.88M | Buy |
22,727
+1,154
| +5% | +$253K | 0.36% | 75 |
|
|
2020
Q4 | $5.1M | Buy |
21,573
+5,650
| +35% | +$1.3M | 0.5% | 55 |
|
|
2020
Q3 | $4.33M | Sell |
15,923
-2,000
| -11% | -$552K | 0.48% | 53 |
|
|
2020
Q2 | $5.2M | Buy |
17,923
+13,109
| +272% | +$3.55M | 0.49% | 48 |
|
|
2020
Q1 | $1.15M | Sell |
4,814
-1,720
| -26% | -$395K | 0.22% | 97 |
|
|
2019
Q4 | $1.43M | Sell |
6,534
-2,450
| -27% | -$496K | 0.12% | 193 |
|
|
2019
Q3 | $1.52M | Buy |
8,984
+1,025
| +13% | +$181K | 0.12% | 188 |
|
|
2019
Q2 | $1.46M | Buy |
7,959
+780
| +11% | +$136K | 0.12% | 187 |
|
|
2019
Q1 | $1.32M | Buy |
7,179
+1,550
| +28% | +$286K | 0.11% | 201 |
|
|
2018
Q4 | $933K | Sell |
5,629
-90
| -2% | -$15.6K | 0.09% | 244 |
|
|
2018
Q3 | $1.1M | Buy |
5,719
+590
| +12% | +$105K | 0.09% | 234 |
|
|
2018
Q2 | $872K | Sell |
5,129
-1,380
| -21% | -$214K | 0.08% | 267 |
|
|
2018
Q1 | $1.06M | Buy |
6,509
+2,800
| +75% | +$457K | 0.1% | 235 |
|
|
2017
Q4 | $556K | Hold |
3,709
| – | – | 0.05% | 356 |
|
|
2017
Q3 | $564K | Sell |
3,709
-1,700
| -31% | -$256K | 0.06% | 335 |
|
|
2017
Q2 | $697K | Buy |
5,409
+2,200
| +69% | +$265K | 0.07% | 284 |
|
|
2017
Q1 | $351K | Hold |
3,209
| – | – | 0.04% | 409 |
|
|
2016
Q4 | $236K | Hold |
3,209
| – | – | 0.03% | 449 |
|
|
2016
Q3 | $280K | Buy |
3,209
+870
| +37% | +$82.2K | 0.03% | 422 |
|
|
2016
Q2 | $201K | Buy |
+2,339
| New | +$202K | 0.03% | 429 |
|
Other funds holding VRTX
Meiji Yasuda Asset Management's VRTX Position: Q2 2026 in Review
Meiji Yasuda Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 43% in Q2 2026, buying an estimated $1.68M and bringing the position to 12,740 shares worth $6.33M. The position accounts for 0.28% of the portfolio, ranked #107.
Meiji Yasuda Asset Management first reported a position in VRTX in Q2 2016 and has held it in 41 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Meiji Yasuda Asset Management held 12,740 shares of Vertex Pharmaceuticals worth $6.33M as of Q2 2026.
- Meiji Yasuda Asset Management bought 3,800 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.68M.
- Vertex Pharmaceuticals made up 0.28% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #107 holding.
- Meiji Yasuda Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.